Overview


According to FutureWise analysis, the market for Liquid Biopsy in 2023 is US$ 5.1 billion, and is expected to reach US$ 19.84 billion by 2031 at a CAGR of 18.52%.

A liquid biopsy is a less intrusive alternative to surgical biopsies, making it possible to find a tumor with a small blood sample. The most effective therapy for a patient can be determined by looking for DNA traces of the malignancy in the patient's blood. Non-small cell lung cancer (NSCLC) is diagnosed via liquid biopsies, which are also used to screen for NSCLC and as a companion diagnosis for other malignancies, including gastrointestinal, colorectal, breast, prostate, and ovarian cancer. The primary market expansion drivers include liquid biopsy's low cost and efficacy compared to other diagnostic techniques. Growth potential will be continued by fast-track approvals from regulatory agencies, including the US Food and Drug Administration (FDA), for non-invasive cancer detection tests. The market is also expanding due to increased clinical studies to create innovative liquid biopsy assays. Due to its growing use as a prognostic and diagnostic tool, it has excellent potential for market expansion.

Liquid biopsy tests are utilized in various healthcare and research contexts, including hospitals, doctors' offices, pathology labs, and research labs, to better understand the molecular characteristics of cancer. It is a non-invasive blood test that could help physicians, surgeons, and researchers better understand a patient's disease profile and determine the most effective course of treatment to improve cancer patients' survival odds. A simple blood draw, blood plasma nucleic acid extraction, and molecular target amplification are often the first steps in this rapid technique, which enables an examination of the defined biomarkers. Liquid biopsies have several advantages that improve patient safety and the efficiency of cancer therapy, such as simple, non-invasive access to the tumor genome, early cancer identification and detection, characterization of new lesions, and earlier diagnosis of cancer.

FutureWise Market Research has published a report that provides an insightful analysis of liquid biopsy market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the liquid biopsy market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Biocept Inc.
  • Qiagen N.V.
  • Roche Diagnostics.
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Menarini-Silicon Biosystems.
  • Trovagene Inc.
  • Guardant Health, Inc.
  • Mdxhealth SA.
  • Genomic Health Inc.

Recent developments by key players in Liquid Biopsy Market:

  • In August 2022- The CE-Market Predicine CARE for PredicineCARE, a liquid biopsy for genomic profiling that targets 152 genes in patients with cancer, was introduced by Predicine.

The primary drivers boosting the liquid biopsy market are the rising incidence of cancer around the globe and the growing public awareness of the availability of various non-invasive treatments. The new liquid biopsy approach has a lot of other benefits, such as speedy results, low cost, early prognosis, ability to overcome tumor heterogeneity, low danger, and non-invasiveness. All these advantages over traditional diagnostics have fueled the adoption of liquid biopsy among patients worldwide, and this acceptance is expected to lead to a significant increase in demand during the projection period. Moreover, NGS technology allows for the detection of a wide range of mutations that may lead to cancer and potential resistance mechanisms that may have emerged from pre-existing clones following therapy. Thanks to recent, rapid advancements in NGS technology, high-accuracy sequencing is substantially less expensive. The use of this technique in focused panels enables the screening of unidentified variations and allows for the precise and sensitive detection of ctDNA mutations. The increased demand for non-invasive diagnostics and treatments brought on by the widespread adoption of modern technology is anticipated to fuel the market demand. Due to the rising investments made by market participants in clinical trials to develop novel diagnostic solutions, the market is growing exponentially. Key market participants' involvement in the sector is anticipated to open up prospects for the market and other market participants, boosting revenue for this target market. However, blood collection is a delicate process used in liquid biopsy that can be severely ruined by carelessness or a lack of experience. Such operations require professionals with substantial training and qualifications in the technology and mechanism. The lack of qualified staff needed to operate the machinery is a significant factor that could restrict the demand of the liquid biopsy market.

By Product

  • Assays Kits
  • Instruments
  • Services

By Circulating Biomarker

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers

By Clinical Application

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring Orthopedics

By Application

  • Oncology
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma Cancer
    • Other Cancers
  • Non-Cancer Application

By End User

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic and Research Centers
  • Other End Users

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Rest of the World

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022, due to a high incidence of cancer, quick technical development, and expanding government activities. Additionally, throughout the projection period, the regional market is anticipated to rise due to new FDA approvals for liquid biopsy testing, quick technological improvements, and fierce competition amongst biotechnology companies. Also, growing government initiatives, such as free screening for cervical, breast, and lung cancer, and increased government, research institute, and business collaborations for distributing and supplying these tests further propel market’s growth in this region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
     
  • Growth prospects
  • SWOT analysis
  • Key trends Key
  • data-points affecting market growth
  • To provide with an exhaustive analysis on the global Liquid Biopsy Market by product, by circulating biomarker, by clinical application, by application, by end user and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Liquid Biopsy Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global Liquid Biopsy Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Liquid Biopsy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Liquid Biopsy Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Assays Kits
        2. Instruments
        3. Services

  • 8.   Global Liquid Biopsy Market, By Circulating Biomarker Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Circulating Tumor Cells (CTCs)
        2. Circulating Tumor DNA (ctDNA)
        3. Cell-Free DNA (cfDNA)
        4. Extracellular Vesicles (EVs)
        5. Other Circulating Biomarkers

  • 9.   Global Liquid Biopsy Market, By Clinical Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Early Cancer Screening
        2. Therapy Selection
        3. Treatment Monitoring
        4. Recurrence Monitoring Orthopedics

  • 10.   Global Liquid Biopsy Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
         1.1. Lung Cancer
         1.2. Breast Cancer
         1.3. Colorectal Cancer
         1.4. Prostate Cancer
         1.5. Melanoma Cancer
         1.6. Other Cancers
        2. Non-Cancer Application

  • 11.   Global Liquid Biopsy Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Reference Laboratories
        2. Hospitals and Physician Laboratories
        3. Academic and Research Centers
        4. Other End Users

  • 12.   North America Liquid Biopsy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Liquid Biopsy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Liquid Biopsy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.  Asia Pacific Liquid Biopsy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.  Middle East and Africa Liquid Biopsy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Biocept, Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Qiagen N.V.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Roche Diagnostics
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bio-Rad Laboratories, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Myriad Genetics, Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Menarini-Silicon Biosystems
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Trovagene, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Guardant Health, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Mdxhealth SA
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Genomic Health, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME key takeaway points for Client
Partner

Our Clients